Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? the time has come for GLP-1 receptor agonists!

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 2107-2111

  Schwartz, Stanley ^a   Defronzo, Ralph A ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ARTICLE; CARDIOVASCULAR RISK; CELL FUNCTION; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; INTENSIVE CARE; LOW DRUG DOSE; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT CARE; SCREENING;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INPATIENTS; INSULIN; RECEPTORS, GLUCAGON;

EID: 84885964455     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2060     Document Type: Article

References (44)

1. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006;29: 1955-1962
2. Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011;154: 260-267
3. Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE. Unrecognized diabetes among hospitalized patients. Diabetes Care 1998;21:246-249
4. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemiarelated mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009;37:3001-3009
5. Muhlestein JB, Anderson JL, Horne BD., et al.; Intermountain Heart Collaborative Study Group. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003; 146:351-358
6. Kosiborod M, Inzucchi SE, Krumholz HM., et al. Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med 2009;169: 438-446
7. Malmberg K, Rydén L, Efendic S., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65
8. van den Berghe G, Wouters P, Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-1367
9. Vlasselaers D, Milants I, Desmet L., et al. Intensive insulin therapy for patients in pediatric intensive care: a prospective, randomised controlled study. Lancet 2009;373:547-556
10. Malmberg K, Rydén L, Wedel H., et al.; DIGAMI 2 Investigators. Intense metabolic control bymeans of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26:650-661
11. van den Berghe G, Wilmer A, Hermans G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-461
12. Finfer S, Chittock DR, Su SY., et al.; NICESUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297
13. Brunkhorst FM, Engel C, Bloos F., et al.; German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-139
14. Preiser JC, Devos P, Ruiz-Santana S., et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 2009;35:1738-1748
15. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care 2009; 32:1153-1157
16. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011;54:10-18
17. Cervera A, Wajcberg E, Sriwijitkamol A., et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2008;294:E846-E852
18. Degn KB, Juhl CB, Sturis J., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187-1194
19. Courrèges JP, Vilsbøll T, ZdravkovicM., et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008;25: 1129-1131
20. Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med 2011;124(Suppl): S35-S53
21. Del Prato S, Leonetti E, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 1994;37: 1025-1035
22. Rensing KL, Reuwer AQ, Arsenault BJ., et al. Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? Diabetes Obes Metab 2011;13:1073-1087
23. Arcaro G, Cretti A, Balzano S., et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002;105:576-582
24. Gerstein HC, Miller ME, Byington RP., et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
25. Patel A, MacMahon S, Chalmers J., et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
26. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011;10:22-32
27. Nikolaidis LA, Mankad S, Sokos GG., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109: 962-965
28. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699
29. Sokos GG, Bolukoglu H, German J., et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100:824-829
30. Müssig K, Oncü A, Lindauer P., et al. Effects of intravenous glucagon-like peptide- 1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol 2008;102:646-647
31. Shamoon H, Hendler R, Sherwin RS. Synergistic interactions among antiinsulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab 1981;52:1235-1241
32. van Raalte DH, van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagonlike peptide-1 receptor agonist treatment prevents glucocorticoid- induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011;34:412-417
33. van Raalte DH, Nofrate V, Bunck MC., et al. Acute and 2-week exposure to prednisolone impair different aspects of betacell function in healthymen. Eur J Endocrinol 2010;162:729-735
34. Ranta F, Avram D, Berchtold S., et al. Dexamethasone induces cell death in insulinsecreting cells, an effect reversed by exendin-4. Diabetes 2006;55:1380-1390
35. DeFronzo RA, Sherwin RS, Felig P. Synergistic interactions of counterregulatory hormones: a mechanism for stress hyperglycemia. Acta Chir Scand Suppl 1980; 498:33-42
36. Ortega AE, Peters JH, Incarbone R., et al. A prospective randomized comparison of the metabolic and stress hormonal responses of laparoscopic and open cholecystectomy. J Am Coll Surg 1996;183: 249-256
37. Del Prato S, Castellino P, Simonson DC, DeFronzo RA. Hyperglucagonemia and insulin-mediated glucose metabolism. J Clin Invest 1987;79:547-556
38. Meier JJ, Weyhe D, Michaely M., et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 2004;32:848-851
39. Marso SP, Al-Amoodi M, Riggs L., et al. Administration of intravenous exenatide to patients with sustained hyerglycemia in the coronary ICU (Abstract). Diabetes 2011;60(Suppl. 1):A75
40. Kohl B, Hammond M, Schwartz S, Ochroch A. Intravenous exenatide (Byetta) for the treatment of perioperative hyperglycemia (Abstract). Society of Critical Care Medicine's 40th Critical Care Congress, 15-19 January 2011
41. Mecott GA, Herndon DN, Kulp GA., et al. The use of exenatide in severely burned pediatric patients. Crit Care 2010;14:R153
42. Garber AJ, King AB, Del Prato S., et al.; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin apart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target noninferiority trial. Lancet 2012;379:1498-1507
43. Inzucchi SE, Siegel MD. Glucose control in the ICU-how tight is too tight? N Engl J Med 2009;360:1346-1349
44. Ellero C, Han J, Bhavsar S., et al. Prophylactic use of anti-emetic medications reduced nausea and vomiting associated with exenatide treatment: a retrospective analysis of an open-label, parallel-group, single-dose study in healthy subjects. Diabet Med 2010;27:1168-1173